Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status

Author(s): Karina Petit, Jean-Francois Biard

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 13 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Marine ecosystems constitute a huge reservoir of biologically active secondary metabolites. Consequently during the last past few decades, several marine-derived molecules have been approved for anticancer treatment or are under clinical trials. This review reports the present state of the art of the sixteen molecules approved or currently on the clinical pipeline for anticancer chemotherapy. The molecules are classified according to their current status in the phase (approved / phase IV / phase III / phase II / phase I) and data are updated to April 2012.

Keywords: Brentuximab vedotin, Clinical trials, Cytarabine, Elisidepsin, Eribulin, ILX-651, KLH, Marine natural products, MMAE, MMAF, Plinabulin, plitidepsin, PM00104, PM01183, PM060184, Salinosporamide A, Trabectedin, TZT-1027

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [603 - 631]
Pages: 29
DOI: 10.2174/1871520611313040010
Price: $65

Article Metrics

PDF: 53